Riskpilot← Back to searchSign inGet full accessUppsala Therapeutics AB
ABActiveOrg 5590274204Hasselbladsvägen 10Research and experimental development on natural sciences and engineering · NACE 7210Est. 20150 employees
Revenue 2024
SEK 0
EBITDA margin
—
-338% vs 2023
Equity ratio
38.3%
Financial strength
Net profit 2024
SEK -62K
-313% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -62K | -338% |
| Net profit | SEK -62K | -313% |
| Total assets | SEK 80K | -28% |
| Equity | SEK 31K | +11% |
| Employees | 0 | — |
Legal name
Uppsala Therapeutics AB
Org number
5590274204
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
22 september 2015
Share capital
SEK 51 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Aktiebolaget ska bedriva forskning inom biomedicin och därmed förenlig verksamhet.
Address
Hasselbladsvägen 10
Email
opvarghese@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 50 | 110 | 0 | 0 | 0 |
| Staff expenses | — | — | −740 | −314 | −0 |
| EBITDA | −20 | 207 | −342 | −14 | −62 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −20 | 207 | −342 | −14 | −62 |
| Net financials | — | −1 | −1 | −1 | 0 |
| Profit before tax | −20 | 206 | −343 | −15 | −62 |
| Tax | −0 | −41 | — | — | — |
| Net profit | −20 | 165 | −343 | −15 | −62 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 61 | 476 | 155 | 112 | 80 |
| Equity | 29 | 194 | 38 | 28 | 31 |
| Long-term debt | 33 | 187 | 0 | — | — |
| Short-term debt | 0 | 94 | 117 | 84 | 50 |
| Total debt | 33 | 281 | 117 | 84 | 50 |
EBITDA margin
-6210200.0%
This company
15.8%
Market median
-39305163% vs market
20202024
Equity ratio
38.3%
This company
38.2%
Market median
+0% vs market
20202024
Return on equity
-201.2%
This company
18.4%
Market median
-1193% vs market
20202024
Net profit margin
-6192600.0%
This company
8.1%
Market median
-76451952% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.61×
This company
0.62×
Market median
-160% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
VD Chief Executive Officer | Chief Executive Officer | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2024 | |
| Deputy Board Member | 2025 | |
| Board of Directors | 2022 | |
| Former (2) | ||
| Chairman | 2022 – 2024 | |
| Board of Directors | 2024 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Uppsala Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Victor Daniel Hartman | Chief Executive Officer | 0 companies |
| Jöns Gunnar Hilborn | Chairman | 0 companies |
| Christos Leliopoulos | Board of Directors | 0 companies |
| Podiyan Oommen Oommen | Chairman | 0 companies |
| Julie Oommen | Deputy Board Member | 0 companies |
| Varghese Oommen Podiyan | Board of Directors | 0 companies |